United Therapeutics (UTHR) Tops Q3 EPS by 26c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $501.27 -2.04%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $1.52, $0.26 better than the analyst estimate of $1.26. Revenue for the quarter came in at $242.5 million versus the consensus estimate of $227.63 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
- Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
